Tumor-infiltrating lymphocytes

But we will get patients home faster than any other transplant or cell therapy program that I know of.

We'll get someone who's had an auto transplant CAR T or TILS home after day 14 if they're safe, and even after day 28 after an allotransplant if they're safe.

We shift to this model called shared care then.

So shared care is not the patient is being dumped on the local doctor's office.

So there are other examples of immunotherapies that we're using now to treat melanoma.

I'm thinking of TILs in the checkpoint inhibitor refractory space.

So I think all of these other immunotherapy modalities, the question is how do you put them together with immune checkpoint inhibitors? So there's no doubt that to treat melanoma from stages...

two to four, the backbone.

You've got CAR T-cells.

You've got TILs.

And now we've got our personalized therapeutic.

It's not preventative.

If you think about, you know, going in and looking at DNA and you think about all the millions of cells that we have, you really need something that can quickly go through all this information and make some assumptions, and that's really what AI has enabled us to do, which is very exciting.

So number three on the list, kind of rounding out the top three, and I think a lot of people have probably heard this too, this is next generation cell therapy.

So CAR-Ts, TILs, and NK cells, and basically these are adopted cell therapies that involve extracting the patient's immune cells, such as T cells, which are natural cancer killers.

And why they take-- when they take them out of your body, Adrienne, they actually train them to attack the cancer cells.

[laughs]

Hello, everyone, and thank you for tuning into ASTCT Talks, the official podcast of the American Society of Transplantation and Cellular Therapy.

In this episode, we'll explore the emerging role of tumor-infiltrating lymphocytes or TIL therapy in sarcoma.

Before we begin, I'll briefly introduce myself for those who may not know me.

I'm Dan Olsen.

I'm a medical oncologist at the University of Chicago, where I co-lead our melanoma and sarcoma programs, as well as our solid tumor cellular therapy program.

I'll be serving as a guest host for ASTCT Talks, covering TIL therapy in this episode and several more in the coming months.

If you don't want to miss them, please subscribe to wherever you're listening.

And if you enjoy this episode, please consider sharing it with your network.

I printed, I saved the, uh, K8.

Here it is, the tethered TIL.

If you go online, you can find the K8, and I suggest everyone save it to your desktop.

Gotta pull it up here.

Um, they just kind of entered some of the same information they gave six months ago, so some of this is not fresh, okay? We were hoping for fresh data on non-small cell lung cancer.

It's not here yet.

So let's get into the TIL 5001.

Now, here's why this is very, very important, and this is considered the Holy Grail, but let me backtrack first.